Plant Name: Viola philippica
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: |
|---|
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 3.019E-11 | 3.287E-07 | CYP1A1, CYP1A2, CYP1B1, CYP2D6, CYP3A4 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 2.474E-10 | 1.347E-06 | ALOX15, CYP1A1, CYP1A2, CYP1B1, CYP2D6, CYP3A4, XDH |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 1.080E-09 | 3.382E-06 | CYP1A1, CYP1A2, CYP1B1, CYP2D6, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 1.398E-09 | 3.382E-06 | CA12, CA13, CA7, CA9 |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 2.210E-08 | 3.008E-05 | CYP1A2, CYP2D6, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 5.944E-08 | 6.472E-05 | CA12, CA13, CA7, CA9 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 1.322E-07 | 1.186E-04 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 1.362E-07 | 1.186E-04 | CA12, CA13, CA7, CA9 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 2.208E-07 | 1.849E-04 | CYP1A1, CYP1A2, CYP1B1, CYP2D6, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 2.421E-07 | 1.941E-04 | CYP1A2, CYP2D6, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0017144; drug metabolic process | 9.135E-07 | 5.850E-04 | ABCC1, ALDH1A1, CYP1A1, CYP1A2, CYP1B1, CYP2D6, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 1.454E-06 | 8.798E-04 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0065007; biological regulation | GO:0006919; activation of cysteine-type endopeptidase activity involved in apoptotic process | 1.709E-06 | 1.006E-03 | CASP1, CASP7, MAPT, XDH |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 1.934E-06 | 1.080E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0008152; metabolic process | GO:0009822; alkaloid catabolic process | 3.375E-06 | 1.709E-03 | CYP2D6, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 3.375E-06 | 1.709E-03 | CYP1A1, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0034754; cellular hormone metabolic process | 5.140E-06 | 2.382E-03 | ALDH1A1, CYP1A1, CYP1B1, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 6.746E-06 | 2.825E-03 | CYP1A1, CYP1A2 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 6.746E-06 | 2.825E-03 | CYP1A2, CYP3A4 |
| BP | GO:0050896; response to stimulus | GO:0014070; response to organic cyclic compound | 7.616E-06 | 3.129E-03 | CA9, CASP1, CASP7, CYP1A1, CYP1A2, CYP1B1, NFKB1 |
| MF | GO:0003824; catalytic activity | GO:0101020; estrogen 16-alpha-hydroxylase activity | 1.124E-05 | 4.292E-03 | CYP1A1, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0002933; lipid hydroxylation | 1.684E-05 | 6.112E-03 | CYP1A1, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0009804; coumarin metabolic process | 2.356E-05 | 7.894E-03 | CYP1A1, CYP2D6 |
| BP | GO:0008152; metabolic process | GO:2000377; regulation of reactive oxygen species metabolic process | 3.013E-05 | 9.941E-03 | CYP1B1, HIF1A, MAPT, XDH |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 1.096E-08 | 4.383E-07 | CYP2D6; CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 2.118E-09 | 1.695E-07 | CA12; CA7; CA9; CA13 |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 3.673E-07 | 9.793E-06 | CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 5.833E-07 | 1.167E-05 | CYP1A2; ALDH1A1; CYP1A1; CYP3A4 |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 1.489E-06 | 2.383E-05 | CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
| hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 9.614E-06 | 1.048E-04 | CYP1A2; CYP1A1; CYP1B1 |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 3.582E-06 | 4.776E-05 | CYP1A2; ALOX15; CYP3A4 |
| hsa05134 | Legionellosis_Homo sapiens_hsa05134 | 2.527E-05 | 2.246E-04 | CASP7; CASP1; NFKB1 |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 4.999E-05 | 3.999E-04 | CYP2D6; CYP1A2; CYP3A4 |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 1.853E-04 | 1.235E-03 | CYP1A2; ALOX15; ALDH1A1; CYP1A1; CYP3A4; HSD17B10; XDH |
| hsa05133 | Pertussis_Homo sapiens_hsa05133 | 6.417E-05 | 4.667E-04 | CASP7; CASP1; NFKB1 |
| hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 6.928E-04 | 4.263E-03 | CASP7; MAPT; HSD17B10 |
| hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 1.248E-03 | 6.655E-03 | CYP1A1; CYP1B1 |
| hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 3.536E-03 | 1.532E-02 | ABCC1; CYP1B1; NFKB1 |
| hsa00983 | Drug metabolism - other enzymes_Homo sapiens_hsa00983 | 1.057E-03 | 6.040E-03 | CYP3A4; XDH |
| hsa04621 | NOD-like receptor signaling pathway_Homo sapiens_hsa04621 | 1.619E-03 | 8.093E-03 | CASP1; NFKB1 |
| hsa04623 | Cytosolic DNA-sensing pathway_Homo sapiens_hsa04623 | 2.035E-03 | 9.579E-03 | CASP1; NFKB1 |
| hsa04668 | TNF signaling pathway_Homo sapiens_hsa04668 | 5.880E-03 | 2.214E-02 | CASP7; NFKB1 |
| hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 5.175E-03 | 2.070E-02 | HIF1A; NFKB1 |
| hsa05132 | Salmonella infection_Homo sapiens_hsa05132 | 3.639E-03 | 1.532E-02 | CASP1; NFKB1 |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 6.089E-03 | 2.214E-02 | CYP2D6; ALOX15 |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 9.364E-03 | 3.121E-02 | CASP7; NFKB1 |
| hsa04932 | Non-alcoholic fatty liver disease (NAFLD)_Homo sapiens_hsa04932 | 1.082E-02 | 3.464E-02 | CASP7; NFKB1 |
| hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 6.959E-03 | 2.420E-02 | ABCC1; NFKB1 |
| hsa05164 | Influenza A_Homo sapiens_hsa05164 | 1.433E-02 | 4.410E-02 | CASP1; NFKB1 |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 1.048E-05 | 1.048E-04 | CYP1A2; XDH |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | ABCC1; ABCC1; XDH |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A; CA9 |
| C00-D49: Neoplasms | Cancer | C00-C96 | HIF1A; CA9; NFKB1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CYP2D6 |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | CASP1 |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | HIF1A; CA9 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | NFKB1 |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9 |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAPT |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | NPSR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | ABCC1 |
| C00-D49: Neoplasms | Breast cancer | C50 | CA9 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | CASP1 |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH |
| G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | MAPT |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | CYP2D6 |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | CYP2D6 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4 |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | XDH |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | MAPT |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | CASP1 |